Class IIOngoingD-0007-2025
Drug recall · October 9, 2024
Pluvicto recall
Why: CGMP deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Pluvicto, 1000 MBq/mL (27 mCi/mL), lutetium, LU 177, vipivotide tetraxetan injection, Single-dose vial, Sterile, Manufacturer Advanced Accelerator Applications, 57 E. Willow Street, NJ 07041, Millburn USA. NDC 69488-0010-61
- Lots / codes
Lot#: LPS240919B-16, 24-Sep-2024 Lot#: LPS240920B-16, 25-Sep-2024 Lot#: LPS240920C-16, 25-Sep-2024
- Quantity
- 99 doses
- Company
- Advanced Accelerator Applications USA, Inc., Millburn, NJ
- Distribution
- FL, MA, NJ, NY, PA, and VA
- Initiated
- September 23, 2024 · Voluntary: Firm initiated
- Classified
- October 3, 2024
- Reported
- October 9, 2024
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.